论文部分内容阅读
目的探讨原发性肝癌患者应用肝动脉化疗栓塞术(TACE)介入治疗的临床疗效以及安全性。方法选取从2006年1月至2009年1月在本院进行入院治疗的68例原发性肝癌患者作为研究对象,所有患者均经入院检查确诊为原发性肝癌,两组患者在性别、年龄、病程及临床表现和辅助检查等一般情况方面比较差异无统计学意义(P>0.05)。按照随机平均原则分为对照组和观察组,各34人。观察组应用肝动脉化疗栓塞术(TACE)进行治疗,具体方案为碘化油10ml+表阿霉素50mg+羟基喜树碱10mg+5-氟尿嘧啶1g+造影剂;对照组应用肝动脉栓塞疗法(TAE)进行治疗,具体应用的药物有表阿霉素50mg+羟基喜树碱10mg+卡铂80mg。观察两组治疗后的AFP含量变化、总有效率、不良反应以及累计生存率。结果观察组和对照组治疗后AFP含量、总有效率、不良反应以及累计生存率与治疗前比较,差异有统计学意义(P<0.05),治疗后两组之间比较,差异有统计学意义(P<0.05)。结论介入治疗对原发性肝癌患者的治疗是安全有效的,其中肝动脉化疗栓塞术(TACE)比肝动脉栓塞疗法(TAE)更有效、更安全、效果更好,提高患者的生命和生活质量,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of hepatic arterial chemoembolization (TACE) interventional therapy in patients with primary liver cancer. Methods From January 2006 to January 2009 in our hospital for admission 68 cases of primary liver cancer patients as the research object, all patients were admitted to hospital for diagnosis of primary liver cancer, two groups of patients in gender, age , The course of disease and clinical manifestations and auxiliary examination and other general aspects of the difference was not statistically significant (P> 0.05). According to the principle of randomness, the control group and the observation group were divided into 34 groups. The observation group was treated with transcatheter arterial chemoembolization (TACE). The specific protocol was iodized oil 10ml + epirubicin 50mg + hydroxycamptothecin 10mg + 5-fluorouracil 1g + contrast agent; control group was treated with TAE Treatment, the specific application of epirubicin drugs 50mg + hydroxycamptothecin 10mg + carboplatin 80mg. AFP content changes, total effective rate, adverse reactions and cumulative survival rate were observed after treatment. Results The AFP content, total effective rate, adverse reaction and cumulative survival rate in the observation group and the control group after treatment were significantly different from those before treatment (P <0.05), and there was significant difference between the two groups after treatment (P <0.05). Conclusions Interventional treatment is safe and effective for the treatment of patients with primary liver cancer. Among them, TACE is more effective, safer and better than transcatheter arterial embolization (TAE) and improves the life and quality of life ,Worthy of clinical application.